Allon Appoints Professor Trevor Robbins to Scientific Advisory Board
August 30, 2006
VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Aug. 30, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that Professor Trevor Robbins has been appointed to its Scientific Advisory Board effective August 24th, 2006.
Professor Robbins is the Director of the Cambridge MRC Centre in Behavioural and Clinical Neuroscience focused on such conditions as Parkinson's, Huntington's and Alzheimer's diseases, frontal lobe injury, schizophrenia, depression and other developmental syndromes such as attention deficit/hyperactivity disorder. Professor Robbins currently holds the Chair of Experimental Psychology and is Head of Department, where his main work concentrates on the functions of the frontal lobes of the brain and their connections with other regions that are relevant to neurological disorders and psychiatric conditions.
"We are fortunate to be able to bring Professor Robbins' extensive experience and expertise in behavioral and clinical neuroscience into Allon's Scientific Advisory Board," said Professor Illana Gozes, Allon's founder and Chair of the Scientific Advisory Board. "Professor Robin's innovative and pioneering work in cognitive assessment tools will have a direct impact in supporting the development of our products in neuroprotection."
Over the course of his career, Professor Robbins has been included on a list of the 100 most cited neuroscientists by ISI, has published nearly five hundred full papers in scientific journals and co-edited three books (Psychology for Medicine: The Prefrontal Cortex; Executive and Cognitive Function, and Disorders of Brain and Mind). In addition to his lengthy and distinguished career at the University of Cambridge, Professor Robbins is also a Fellow of the British Psychology Society and won that Society's inaugural Distinguished Scientist Aware in 2001. He was also President of the British Association of Psychopharmacology from 1996 to 1997, Editor the Journal Psychopharmacology since 1980 and joined the editorial board of Science in January 2003. During this time he was also a member of the Medical Research Council (UK) and chaired the Neuroscience and Mental Health Board from 1995 until 1999.
About Allon
Allon Therapeutics Inc. is a clinical-stage Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer's, cognitive impairment, stroke, traumatic brain injury, multiple sclerosis and neuropathy. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection CompanyTM) and based in Vancouver.
Forward-Looking Statements
There are forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, Allon's stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market Allon's products, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.
CONTACT INFORMATION
Allon Therapeutics Inc.
Gordon McCauley, President & CEO
Investor and Media Contact
(604) 736-0634 or Cell: (604) 218-4742
(604) 736-1616 (FAX)
gmccauley@allontherapeutics.com
www.allontherapeutics.com
